期刊文献+

1352例狼疮性肾炎的临床与免疫学特征 被引量:48

Clinical and immunological features of 1352 Chinese patients with lupus nephritis
下载PDF
导出
摘要 目的:单中心分析1352例狼疮性。肾炎(LN)的流行病学特点、。肾脏病理类型与临床表现和免疫学异常的联系。方法:1986至2005年间在解放军。肾脏病研究所住院并行肾活检的LN患者1352例。肾活检病理类型按照2003年ISN/RPS分型方案,Ⅴ型与Ⅳ型或Ⅲ型并存的类型记录为Ⅴ+Ⅳ型或Ⅴ+Ⅲ型。临床资料来自病史记载,实验室指标取自首次肾活检时的检查结果。回顾性分析患者一般资料、病理类型分布、各病理类型的临床和免疫学特征。结果:1352例患者均为汉族,女性1193例(占88.2%),男性159例(11.8%),年龄8—60岁[平均(27.3±9.2)岁],18—50岁者占80%。各病理类型比例分别为Ⅳ型49.1%,Ⅴ型14.4%、Ⅱ型14.2%、V+Ⅳ型11.7%、Ⅲ型5.6%和Ⅴ+Ⅲ型5.0%。女性Ⅱ型和Ⅲ型比例显著高于男性,男性Ⅳ型比例高于女性(59.7%vs47.6%,P〈0.01)。各类型。肾脏和。肾外脏器损害的临床及免疫学特征:Ⅱ型以蛋白尿,面部红斑、发热、关节损害为特征,血清抗-dsDNA抗体和低补体血症比例低;Ⅲ型患者主要表现为血尿,关节炎、皮肤血管炎和血清抗中性粒细胞胞浆抗体(ANCA)阳性率高(10.3%)。Ⅳ型患者肉眼血尿和急性。肾衰发生率最高,浆膜腔炎、血清抗-dsDNA抗体和低C4血症比例显著高于其它类型。Ⅴ型患者主要表现为蛋白尿或伴少量血尿,肾外脏器损害、血清抗-dsDNA抗体阳性和低C4血症比例低。Ⅴ+Ⅳ型临床和免疫学特点与Ⅳ型类似,但。肾病性蛋白尿比例显著增高(52.6%掷31.6%),ANCA阳性率低(5.7%vs0)。Ⅴ+Ⅲ型。肾病性蛋白尿比例与Ⅴ型相似,血尿程度与Ⅲ型相同,ANCA阳性和低C4血症比例低于Ⅲ型。抗心磷脂抗体可见于各型LN,但Ⅱ型、Ⅲ型和Ⅴ型阳性率较高(分别为34.1%,34.8%,32.6%)。结论:本组LN病理类型以Ⅳ型为主,Ⅴ型与Ⅳ或Ⅲ型并存者并不少见。且尿蛋白较单一病变者更重。Ⅲ型和Ⅱ型主要见于女性,男性狼疮Ⅳ和Ⅴ+Ⅳ型比例高于女性。LN不同病理类型具有一定的临床和免疫学特征,反映了不同的免疫发病机制,从而影响免疫抑制治疗方案。 Objective:To analyze the clinical and immunological features of 1 352 Chinese patients with lupus nephritis in a single-center. Methodology:1352 LN patients in Jingling Hospital from 1986 to 2005 were included in this study. All patients had renal biopsy. The histological classifications were categorized according to 2003 ISN/RPS classification (Class Ⅰ and Ⅵ were not included in the study). The cmbined class of Ⅳor Ⅲ and Ⅴwere recorded as Ⅳ+ Ⅴor Ⅴ+Ⅲ. Results:l 193 (88.2%) females, and 159(11.8%) males were all Han Chinese, 80% of them were from l8 to 50 years old ( mean 27.3 + 9. 2 years). The renal histological classes showed class Ⅱ ( 14. 2% ) ,Ⅲ (5.6%) , Ⅳ(49. 1%), Ⅴ(14.4%), Ⅴ+Ⅳ(11.7%) and Ⅴ+Ⅲ(5%). The proportion of class Ⅱ (15.2%) and Ⅲ (6. 2%) in females was higher than that in males (6. 9% and 0. 6% respectively, P 〈0. 05) , while class Ⅳ was more common in males than that in females (59. 7% vs 47.6%, P 〈0.01 ). The incidence of extra-renal manifestations including malar rash, fever, arthritis and anemia were higher in class Ⅱ than that in other types. The Serositis, positive anti-dsDNA antibody and low CA were more frequent in class Ⅳ and Ⅴ+ Ⅳ, but less in class Ⅴ. The skin vasculitis and serum ANCA ( all MPO-ANCA) were more common in class Ⅲ( 10. 3% ), Ⅳ(5.7%) and Ⅴ+ Ⅲ(3.2%). The anticardiolipin antibodies were detected in all types but higher in class Ⅱ (34. 1%), Ⅲ (34. 8%), Ⅴ(32.6%) and type Ⅳ(26. 1%), while Cryoglobulinemia was more prominent in class Ⅴ + Ⅲ(69.4%), type Ⅴ (59%) and Ⅴ + Ⅳ (46. 3% ). The patients with hematuria in class Ⅱ(18%) and Ⅴ (30%) were much less than that in Ⅳ (89%), Ⅴ +Ⅳ (87%), Ⅴ + Ⅲ (79%) and Ⅲ (63%), while gross hematuria and RPGN were only found in class Ⅳ (10%, 27%), Ⅴ + Ⅳ (6. 3%, 20. 9% ), Ⅴ + Ⅲ(6.3%, 6%) and Ⅲ (3.9%, 1.3%) but none in class Ⅱ and Ⅴ. The incidence ofnephrotic syndrome was higher in class Ⅴ +Ⅳ (52.5%) than that in class Ⅳ (31.6%), class Ⅴ (34. 9%) and Ⅴ + Ⅲ (35.8%). Conclusion: Lupus nephritis class Ⅳ was the most common type in this study. The segmental or diffuse glo- merular proliferation combined with membranous lesion was also common and should be identified. The Sex difference influ- enced the pattern of histological types. The correlation between histological class and clinical-immunological features might be associated with unique immunopathogenesis.
出处 《肾脏病与透析肾移植杂志》 CAS CSCD 2006年第5期401-408,442,共9页 Chinese Journal of Nephrology,Dialysis & Transplantation
关键词 狼疮性肾炎 病理类型 临床表现 免疫学特征 luus nephritis histological class clinic features immunological features
  • 相关文献

参考文献37

  • 1Li LS,Liu ZH.Epidemiologic data of renal diseases from a single unit in China:Analysis based on 13519 renal biopsy.Kidney Int,2004,66:920-923.
  • 2Cervera R,Khamashta MA,Font J,et al.Morbidity and mortality in systemic lupus erythematosus during a 10-year period:a comparison of early and late manifestations in a cohort of 1,000 patients.Medicine (Baltimore),2003,82(5):299-308.
  • 3Cervera R,Khamashta MA,Font J,et al.Systemic lupus erythmatosus:Clinical and immunologic patterns of disease expression in a cohort of 1000 patients.Medicine,1993,72(2):113-124.
  • 4Font J,Ramos-Casals M,Garcia-Carrasco M,et al.Clusters of clinical and immunologic features in systemic lupus erythematosus:analysis of 600 patients from single center.Semin Arthritis Rheum,2004,33:217-230.
  • 5Mok CC,Lau CS,Chan TM,et al.Clinical characteristics and outcome of southern Chinese males with systemic lupus erythematosus.Lupus,1999,8:188-196.
  • 6Xie SK,Feng SF,Fu H.Long term follow-up of patients with systemic lupus erythematosus.J Dermatol,1998,25(6):367-373.
  • 7Hochberg MC.Updating the American College of Rheumatology revised criteria for classification of systemic lupus erythematosus.Arthritis Rheum,1997,40:1725-1726.
  • 8黎磊石,俞雨生,王庆文,唐政.3600例经皮穿刺肾活检操作的体会[J].肾脏病与透析肾移植杂志,1992,1(1):60-63. 被引量:28
  • 9姚小丹,王庆文,俞雨生,黎磊石.一种更实用更安全的肾活检技术——斜角进针负压吸引法[J].肾脏病与透析肾移植杂志,1993,2(5):421-425. 被引量:65
  • 10Weening JJ,D'agati D,Schwartz M,et al.The classification of glomerulonephritis in systemic lupus erythematosus revisited.Kidney Int,2004,65:521-530.

二级参考文献19

  • 1Churg J,Sobin LH.Lupus nephritis,in renal disease.Classification and atlas of glomerular disease.New York,Igaku-Shoin,1982,127-149.
  • 2Schwartz MM,Lan SP,Bonsib SM,et al.Clinical outcome of three discrete histologic patterns of injury in severe lupus glomerulonephritis.Am J Kidney Dis,1989,13:273 -283.
  • 3Sloan RP,Schwartz MM,Korbet,SM,et al.Long-term outcome in systemic lupus erythematosus membranous glomerulonephritis.J Am Soc Nephrol,1996,7:299-305.
  • 4Weening JJ,D'Agati VD,Schwartz MM,et al.The classification of glomerulonephritis in systemic lupus erythematosus revisited.Kidney Int,2004,65:521-530.
  • 5Hu W,Liu Z,Chen H,et al.Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis.Chin Med J (Engl),2002,115:705 -709.
  • 6Chan TM,Tse KC,Tang CS,et al.Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis.J Am Soc Nephrol,2005,16:1076-1084.
  • 7Ginzler EM,Dooley MA,Aranow C,et al.Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis.N Engl J Med,2005,353:2219 -2228.
  • 8Dooley MA,Cosio FG,Nachman PH,et al.Mycophenolate mofetil therapy in lupus nephritis:Clinical observations.J Am Soc Nephrol,1999,10:833-839.
  • 9Kingdon E J,Mcleannag,Psimenou E,et al.The safety and efficacy of MMF in lupus nephritis:A pilot study.Lupus,2001,10:606 -611.
  • 10Appel GB,Radhakrishnan J,Ginzler E,et al.Controlled randomized trial of Ⅳ cyclophosphamide vs MMF in 140 patients.American College of Rheumatology Meeting; October 23-26,2003;Orlando,FL.

共引文献162

同被引文献512

引证文献48

二级引证文献343

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部